"飯塚病院は、地域医療支援病院、地域がん診療連携拠点病院、救命救急センター、災害拠点病院など11の指定を受けています。診療科目43科、医師364名看護師1067名を含む従業員数2443名(2022年1月時点)で診療を行なっています。"

During the past decade, Iizuka Hospital conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 13 clinical trials were completed, i.e. on average, 52% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 11 clinical trials were completed. i.e. 91.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Iizuka Hospital" #1 sponsor was "Bayer" with 5 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Pfizer" with 5 trials sponsored, "Boehringer Ingelheim" with 4 trials sponsored and "Chugai Pharmaceutical" with 4 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Iizuka Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator and "Guidant Corporation" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Iizuka Hospital" are "Rheumatoid Arthritis" (4 trials), "Anemia" (2 trials), "Heart Failure" (2 trials), "Renal Insufficiency, Chronic" (2 trials) and "Urinary Bladder Neoplasms" (2 trials). Many other conditions were trialed in "Iizuka Hospital" in a lesser frequency.

Most popular intervention types in "Iizuka Hospital" are "Drug" (21 trials), "Biological" (7 trials), "Other" (5 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Cetrelimab" (2 trials), "Darbepoetin alfa" (2 trials), "Molidustat (BAY85-3934)" (2 trials) and "TAR-200" (2 trials). Other intervention names were less common.

The vast majority of trials in "Iizuka Hospital" are 30 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Iizuka Hospital". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Iizuka Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Iizuka Hospital, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".